News | June 11, 2024
Abbott wins CE mark for dual-chamber leadless pacemaker
Abbott's first-of-its-kind i2i technology enables synchronized communication between two leadless pacemakers
Abbott's first-of-its-kind i2i technology enables synchronized communication between two leadless pacemakers
The Gavi Board today approved the Vaccine Alliance's strategy for the five-year period running from 2026 to 2030
Ulcerative Colitis (UC) is a chronic, idiopathic, immune-mediated inflammatory bowel disease (IBD) affecting the large intestine
Partnership to facilitate collaborative research in academia and industry to further progress in life sciences
Through its rare kidney disease portfolio, Novartis is committed to exploring a range of treatment options with different modes of action to slow IgAN progression
Data support the potential of Dupixent as the first new treatment approach in more than a decade and first-ever targeted therapy for COPD
Pivotal OASIS 1 and 2 Phase III studies of investigational compound elinzanetant achieved a statistically significant reduction in frequency and severity of vasomotor symptoms
225Ac-PSMA-Trillium is an investigational next-generation PSMA-targeted alpha therapy with potential to treat patients with advanced metastatic prostate cancer
First BTK inhibitor to show favourable trend in overall survival vs. standard-of-care chemoimmunotherapy in this setting
Late-breaker Phase 3 STRIDE-10 trial presented as an oral presentation at European Society of Clinical Microbiology and Infectious Diseases
Subscribe To Our Newsletter & Stay Updated
